May 24, 2017 5:19 AM ET

Biotechnology

Company Overview of DynPort Vaccine Company LLC

Company Overview

DynPort Vaccine Company LLC provides biopharmaceutical product development programs for government agencies in the United States and internationally. It offers government contracting for business and biopharmaceutical product development, which include program management, risk identification and management, subcontracts management, and financial reporting; health and security protection services for the U.S. and allied governments in protecting soldiers and civilians against emerging diseases and possible bioterror threats; and infectious disease therapeutics. The company also provides consulting services to biotechnology and pharmaceutical companies. It serves government agencies, biotech c...

64 Thomas Johnson Drive

Frederick, MD 21702

United States

Founded in 1997

Phone:

301-607-5000

Fax:

301-607-5099

Key Executives for DynPort Vaccine Company LLC

Director of Finance
Associate Director of Communications
Contracts Director
Director of Program Management Office
Compensation as of Fiscal Year 2016.

DynPort Vaccine Company LLC Key Developments

FDA Grants Orphan Drug Designation to DynPort Vaccine Company for Plague Vaccine

DynPort Vaccine Company LLC was granted Orphan Drug Designation from the U.S. Food and Drug Administration. DVC is developing the recombinant rF1V plague vaccine on behalf of the U.S. Department of Defense (DoD). The vaccine will be used for pre-exposure prophylaxis to combat infection with Yersinia pestis, the causative agent of plague. DVC is a contractor for the Medical Countermeasure Systems Joint Vaccine Acquisition Program (MCS-JVAP) and the sponsor of the associated Investigational New Drug Application for the plague vaccine.

DynPort Vaccine Company LLC Wins Contract

CSRA Inc.'s wholly-owned subsidiary, DynPort Vaccine Company LLC received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to manage a variety of medical product development initiatives for the National Institute of Allergy and Infectious Diseases (NIAID). CSRA'sDynPort Vaccine Company is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years. Under the contract, the company will develop manufacturing processes and analytical test methods, perform product characterization, conduct manufacturing following current good manufacturing practices (cGMP) and provide regulatory services to support the development of new therapies to treat infectious diseases.

DynPort Vaccine Co. Wins $159.44 Million Federal Contract

DynPort Vaccine Co. LLC, Frederick, Maryland, won a federal contract valued at up to $159,444,814 from the U.S. Department of Health and Human Services National Institutes of Health for preclinical services for biopharmaceutical product development.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DynPort Vaccine Company LLC, please visit www.csc.com/dvc. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.